ALG11 Inhibitors
ALG11 inhibitors belong to a distinct chemical class of compounds that play a crucial role in the field of glycobiology, specifically in the realm of protein glycosylation. Glycosylation is a fundamental post-translational modification process in which complex sugar molecules, or glycans, are attached to proteins, thereby influencing their structure, stability, and function. ALG11 inhibitors are a group of chemical compounds designed to target and disrupt the function of ALG11, a key enzyme involved in the early stages of N-linked glycosylation, a specific type of glycosylation that occurs in the endoplasmic reticulum of eukaryotic cells.
ALG11, short for Asparagine-linked glycosylation 11, is an enzyme that catalyzes the transfer of a specific glycan precursor onto nascent proteins during N-linked glycosylation. This enzymatic step is essential for the proper folding and functioning of glycoproteins, which are involved in various cellular processes, including cell-cell communication, signal transduction, and immune response. ALG11 inhibitors work by interfering with the activity of this enzyme, leading to the accumulation of under-glycosylated or misfolded proteins in the endoplasmic reticulum. This disruption can have a profound impact on cellular homeostasis and has implications in various biological contexts, such as protein quality control and cellular stress responses.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Lenvatinib inhibits ALK1 by binding to its ATP-binding site, preventing phosphorylation of downstream signaling proteins like SMAD1/5, thus suppressing angiogenesis and tumor growth. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib inhibits ALK1 signaling by targeting multiple kinases, including ALK1, Raf-1, and VEGFR-2, thereby reducing angiogenesis and tumor growth. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Sunitinib inhibits ALK1 and other kinases, preventing the phosphorylation of downstream targets, such as SMAD1/5, and suppressing angiogenesis and tumor progression. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
Cabozantinib targets ALK1, VEGFR-2, and MET, reducing angiogenesis and tumor growth by inhibiting ALK1 phosphorylation and downstream signaling pathways. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Regorafenib is a multi-kinase inhibitor that targets ALK1, VEGFR-2, and others, disrupting angiogenesis and tumor growth by blocking ALK1-mediated signaling. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Pazopanib inhibits ALK1 and VEGFR-2, leading to reduced angiogenesis and tumor growth by disrupting ALK1-dependent signaling pathways. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
Nintedanib inhibits ALK1, VEGFR, and PDGFR, suppressing angiogenesis by interfering with ALK1-mediated signaling and inhibiting tumor growth. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
Ponatinib is a multi-kinase inhibitor that targets ALK1 and other kinases, inhibiting angiogenesis and tumor growth by blocking ALK1 phosphorylation and downstream pathways. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib inhibits ALK1 and VEGFR-2, disrupting angiogenesis by interfering with ALK1-mediated signaling and inhibiting tumor progression. | ||||||
Tivozanib | 475108-18-0 | sc-475339 | 5 mg | $320.00 | ||
Tivozanib is a VEGFR inhibitor that may indirectly affect ALK1 signaling by reducing VEGF-induced angiogenesis, impacting tumor growth. | ||||||